BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...to radio/chemotherapy (TEDAC) Erytech Pharma S.A. (Euronext:ERYP); ExonHit S.A. (Euronext:ALEHT); InGen BioSciences Group (now part of ExonHit...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...development as their main business. Ark Therapeutics Group plc is now a manufacturing services provider; ExonHit S.A....
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...$27.1M undisclosed round Oct 2002 - reverse-merged with SWX-listed Askilia Holding Diaxonhit (Euronext:ALEHT) (formerly ExonHit Therapeutics...
BioCentury | Dec 24, 2012
Company News

ExonHit, InGen BioSciences deal

...Daixonhit, will continue to trade on Euronext under the symbol "ALEHT" (see BioCentury, Nov. 12). ExonHit S.A....
BioCentury | Dec 3, 2012
Financial News

ExonHit completes private placement

ExonHit S.A. (Euronext:ALEHT), Paris, France Business: Neurology, Cancer, Ophthalmic Date completed: 11/29/12 Type: Private placement Raised: €1.7 million ($2.2 million) Shares: 2.2 million Price: €0.75 Shares after offering: 42.6 million Underwriter: Societe Generale WIR Staff...
BioCentury | Nov 12, 2012
Financial News

ExonHit completes private placement

ExonHit S.A. (Euronext:ALEHT), Paris, France Business: Neurology, Cancer, Ophthalmic Date completed: 11/7/12 Type: Private placement Raised: €4.4 million ($5.6 million) Shares: 5.8 million Price: €0.75 Shares after offering: 40.3 million WIR Staff...
BioCentury | Nov 12, 2012
Company News

ExonHit, InGen BioSciences deal

...in cash and issue €10 million ($12.8 million) in new ExonHit shares to InGen shareholders. ExonHit...
...to the acquisition. Additionally, for each ExonHit share held at a Dec. 14 general meeting, ExonHit...
...The deal, which is subject to ExonHit shareholder approval, is expected to close Dec. 19. ExonHit S.A....
BioCentury | Sep 10, 2012
Emerging Company Profile

Putting a Lid on PDE-4

...effects. At least one other PDE-4B inhibitor is in development for neurological indications. In 2009, ExonHit S.A....
...primary safety endpoint in a Phase IIa trial in patients with mild to moderate AD. ExonHit...
...Business Technology Transfer (STTR) funding to evaluate Tetra's compounds in TBI. Companies and Institutions Mentioned ExonHit S.A....
BioCentury | Jul 23, 2012
Clinical News

AclarusDx: Completed enrollment

...DIALOG trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A....
BioCentury | Jul 23, 2012
Clinical News

AclarusDx: Pilot trial completed enrollment

...pilot trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A....
Items per page:
1 - 10 of 168
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...to radio/chemotherapy (TEDAC) Erytech Pharma S.A. (Euronext:ERYP); ExonHit S.A. (Euronext:ALEHT); InGen BioSciences Group (now part of ExonHit...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...development as their main business. Ark Therapeutics Group plc is now a manufacturing services provider; ExonHit S.A....
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...$27.1M undisclosed round Oct 2002 - reverse-merged with SWX-listed Askilia Holding Diaxonhit (Euronext:ALEHT) (formerly ExonHit Therapeutics...
BioCentury | Dec 24, 2012
Company News

ExonHit, InGen BioSciences deal

...Daixonhit, will continue to trade on Euronext under the symbol "ALEHT" (see BioCentury, Nov. 12). ExonHit S.A....
BioCentury | Dec 3, 2012
Financial News

ExonHit completes private placement

ExonHit S.A. (Euronext:ALEHT), Paris, France Business: Neurology, Cancer, Ophthalmic Date completed: 11/29/12 Type: Private placement Raised: €1.7 million ($2.2 million) Shares: 2.2 million Price: €0.75 Shares after offering: 42.6 million Underwriter: Societe Generale WIR Staff...
BioCentury | Nov 12, 2012
Financial News

ExonHit completes private placement

ExonHit S.A. (Euronext:ALEHT), Paris, France Business: Neurology, Cancer, Ophthalmic Date completed: 11/7/12 Type: Private placement Raised: €4.4 million ($5.6 million) Shares: 5.8 million Price: €0.75 Shares after offering: 40.3 million WIR Staff...
BioCentury | Nov 12, 2012
Company News

ExonHit, InGen BioSciences deal

...in cash and issue €10 million ($12.8 million) in new ExonHit shares to InGen shareholders. ExonHit...
...to the acquisition. Additionally, for each ExonHit share held at a Dec. 14 general meeting, ExonHit...
...The deal, which is subject to ExonHit shareholder approval, is expected to close Dec. 19. ExonHit S.A....
BioCentury | Sep 10, 2012
Emerging Company Profile

Putting a Lid on PDE-4

...effects. At least one other PDE-4B inhibitor is in development for neurological indications. In 2009, ExonHit S.A....
...primary safety endpoint in a Phase IIa trial in patients with mild to moderate AD. ExonHit...
...Business Technology Transfer (STTR) funding to evaluate Tetra's compounds in TBI. Companies and Institutions Mentioned ExonHit S.A....
BioCentury | Jul 23, 2012
Clinical News

AclarusDx: Completed enrollment

...DIALOG trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A....
BioCentury | Jul 23, 2012
Clinical News

AclarusDx: Pilot trial completed enrollment

...pilot trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A....
Items per page:
1 - 10 of 168